Briacell Therapeutics Corp.

(BCTXF)

By |

Profile

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off-the-shelf personalized approach to immunotherapy. The company recently achieved proof-of-concept in a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT, in patients with advanced breast cancer. The trail was being conducted along with the co-development of BriaDX, the Company's companion diagnostic test. Currently, BriaCell is conducting an FDA approved combination study of Bria-IMT with pembrolizumab - Keytruda; manufactured by Merck & Company Inc or ipilimumab - Yervoy manufactured by Bristol-Myers Squibb company for patients with advanced breast cancer.

Contact Information

Website: www.briacell.com
Email: jwerbes@shaw.ca
Main Phone: +1 604 921-1810
Address: 235 - 15th Street
Address 2: Suite 300
State: BC
City / Town: West Vancouver
Country: CAN
Postal Code: V7T 2X1

Issuer Information

Exchange: OTCQB
CEO: William Williams
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 0.069 $ -0.00922 (-11.79%)
Last Price 0.069 Change $ -0.00922 Change % -11.79 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 0.069 High 0.069 Low 0.069 Prev Close 0.07822
Last Trade Volume 300 52 Wk Hi 0.14 52 Wk Low 0.068
Market Cap 11.2 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 162,154,529.00 EPS (TTM) -0.03 PE Ratio N/A Exchange OTCQB

News